Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Gilead Sciences, Inc. (NQ: GILD)
55.60 USD  -0.33 (-0.59%)
Streaming Delayed Price  /  Updated: 1:56 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Stories about Gilead Sciences, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Earnings Expectations for the Week of April 29
April 28, 2013
First-quarter results from General Motors (NYSE: GM ) will be one of the highlights on the earnings front this week. Analysts anticipate that the carmaker will say Thursday its revenue slipped about... Read More
category Earnings , MSO , K , and 73 more.
from Latest Articles from Benzinga.com
A Look Ahead: This Week's ETFs to Watch
April 28, 2013
Last week was another fine one for U.S. stocks as the broader market fought off an array of data points that can only be considered mixed at best to again close higher. With last week's 1.4 percent... Read More
category Earnings , Specialty ETFs , Emerging Market ETFs , and 24 more.
from Latest Articles from Benzinga.com
Fed May Provide a Safety Net for the Market
April 26, 2013
The Fed is expected to repeat its dovish message in the coming week, which could provide a safety net for the market amid a big wave of earnings and the important April jobs report. Read More
category Realogy Corp , Archer Daniels Midland Co , tvcodes/tvearn , and 94 more.
from CNBC.com News
Weekly Preview: Focus Shifts from Earnings to Economy
April 26, 2013
In the upcoming week, the focus of markets will gradually shift from earnings to the economy, especially later in the week, as key reports including the ECB rate decision and the U.S. Non-Farm Payrolls... Read More
category Rate Cuts , Earnings , Global , and 72 more.
from Latest Articles from Benzinga.com
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $52.32
April 26, 2013
from Comtex SmarTrend® News Briefs
Short Sellers Move into Celgene, Regeneron
April 26, 2013
The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN ), Amgen... Read More
category Regeneron Pharmaceuticals , amgen , Benzinga , and 34 more.
from Latest Articles from Benzinga.com
UPDATE 3-AbbVie delivers on strong growth of Humira arthritis drug
April 26, 2013
April 26 (Reuters) - AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially... Read More
category companyNews
from Reuters: Company News
Jim Cramer: 14 Stocks for the Younger Generation
April 25, 2013
If you're in your twenties and you're not currently buying stocks, Cramer thinks you'll regret it. Read More
category Costco Wholesale Corporation , Energy/Oil and Gas , Cummins Inc , and 22 more.
from CNBC.com News
Gilead (GILD) Achieves 100% Rate with Sofosbuvir, Ledipasvir Combo on HCV
April 25, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8278944 for the full story. Read More
from StreetInsider.com News Articles
Gilead Sciences Up 85.4% Since SmarTrend Uptrend Call (GILD)
April 25, 2013
from Comtex SmarTrend® News Briefs
Cramer: Sellers Clobbering Stocks Recklessly?
April 24, 2013
Pockets of weakness in the market have captured Jim Cramer's attention. Is the selling really warranted? Read More
category Biotechnology , tvcodes/tvearn , tvcodes/tvearnings , and 30 more.
from CNBC.com News
Wednesday's ETF with Unusual Volume: BBH
April 24, 2013
The Biotech ETF (BBH) is seeing unusually high volume in afternoon trading Wednesday, with over 225,000 shares traded versus three month average volume of about 73,000. Shares of BBH were off about 3%... Read More
category ETFs
from ETF Channel
StockCall Study on Gilead Sciences, NPS Pharma, InterMune, Seattle Genetics, and Halozyme Therapeutics
April 24, 2013
from ACCESSWIRE
Bearish Moving Average Cross by Gilead Sciences (GILD)
April 24, 2013
from Comtex SmarTrend® News Briefs
UPDATE 1-AbbVie hepatitis C drugs knock out virus at 8 weeks
April 23, 2013
* Bristol-Myers shares up 1.2 percent after promising data Read More
category companyNews
from Reuters: Company News
Noteworthy ETF Inflows: VUG, AAPL, GOOG, GILD
April 23, 2013
Symbols mentioned in this story: VUG, AAPL, GOOG, GILD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... Read More
category ETFs
from ETF Channel
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $54.43
April 23, 2013
from Comtex SmarTrend® News Briefs
Gilead (GILD) to Present Data from Four Sofosbuvir Phase 3s
April 23, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8269689 for the full story. Read More
from StreetInsider.com News Articles
Bristol-Myers oral hepatitis C regimen looks competitive -study
April 23, 2013
* 2 serious side effects likely unconnected to Bristol drugs Read More
category companyNews
from Reuters: Company News
AbbVie hepatitis C drugs knock out virus at 8 weeks
April 23, 2013
April 23 (Reuters) - A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising... Read More
category companyNews
from Reuters: Company News
Gilead Sciences - Trade Flow Report
April 23, 2013
NEW YORK (AVAFIN) -- Block trades serve as a useful indicator for investors trying ... Read More
from AVAFIN
Moody's sees pick-up in pharmaceutical industry M&A in 2013
April 22, 2013
LONDON, April 23 (Reuters) - Cash-rich drug companies are likely to make more acquisitions in 2013 after a thin year for deals in 2012, ratings agency Moody's Investors Service said on Tuesday. Read More
category companyNews
from Reuters: Company News
Maxim Group Raises Gilead Sciences (GILD) Price Target to $97
April 22, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8268370 for the full story. Read More
from StreetInsider.com News Articles
Biotech Mutual Funds Show ETFs Are The Place to Be
April 22, 2013
In March, we compared a a popular energy sector ETF and a comparable mutual fund with the idea being to figure out when relevant factors are considered, which vehicle is best for investors. That... Read More
category Benzinga , XLE , ETFs , and 14 more.
from Latest Articles from Benzinga.com
UPDATE: Morgan Stanley Raises PT on Gilead Sciences on Multiple Positive Factors
April 22, 2013
In a report published Monday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Gilead Sciences (NASDAQ: GILD ), and raised the price target from $46.00 to $65.00. In the report,... Read More
category Benzinga , Morgan Stanley , Price Target , and 3 more.
from Latest Articles from Benzinga.com
Active Buzzers: Citigroup Inc, Boston Scientific Corporation, Morgan Stanley, Gilead Sciences
April 21, 2013
from ACCESSWIRE
A Look Ahead: This Week's ETFs to Watch
April 21, 2013
Market participants cannot look back on the dour performance turned in by U.S. stocks last week. The one where the S&P 500 slumped 2.1 percent and turned not only its worst weekly performance of 2013,... Read More
category Earnings , Specialty ETFs , Emerging Market ETFs , and 26 more.
from Latest Articles from Benzinga.com
Weekly Preview: Earnings Season Continues, Apple In Focus
April 19, 2013
Next week, earnings season continues as investors eye key earnings from technology behemoths Apple (NASDAQ: AAPL ) and chip maker Texas Instruments (NASDAQ: TXN ). Texas Instruments' earnings and... Read More
category S , Earnings , YUM , and 90 more.
from Latest Articles from Benzinga.com
The Markets Now: Stocks Mixed After Tech Company Earnings Reports
April 19, 2013
Plus, Google and Microsoft beat earnings estimates. Read More
category MSFT , DELL , IBM , and 2 more.
from Minyanville Headlines
Vertex News Lifts Biotech ETFs
April 19, 2013
Shares of biotechnology firm Vertex Pharmaceuticals (NASDAQ: VRTX ) are soaring by more than 55 percent early Friday and have touched a new all-time high after the company announced late Thursday that... Read More
category Benzinga , Movers , ETFs , and 18 more.
from Latest Articles from Benzinga.com
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here